CREB Regulated Transcription Coactivator 1 (CRTC1) Antibody

Product Graph
286€ (100 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
CREB Regulated Transcription Coactivator 1 (CRTC1) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx176042
tested applications
WB, IHC, IF/ICC

Description

CREB Regulated Transcription Coactivator 1 (CRTC1) Antibody is a Rabbit Polyclonal antibody against CREB Regulated Transcription Coactivator 1 (CRTC1).

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
CREB Regulated Transcription Coactivator 1 (CRTC1)
Host
Rabbit
Reactivity
Human
Recommended Dilution
WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Unconjugated
Purification
Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography.
Size 1
100 µl
Size 2
200 µl
Size 3
1 ml
Form
Liquid
Tested Applications
WB, IHC, IF/ICC
Buffer
0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.
Availability
Shipped within 5-7 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
Background
Antibody anti-CRTC1
Status
RUO

Descripción

Related Products

FNab08875

CRTC1 antibody

Ver Producto
P9339

Recombinant Human CRTC1

Ver Producto
abx011128

CREB Regulated Transcription Coactivator 1 (CRTC1) Antibody

MECT1 (also known as MucoEpidermoid Carcinoma Translocated 1) functions as a transcriptional coactivator for CREB1, which activates transcription through both consensus and variant cAMP response element (CRE) sites. MECT1 does not appear to modulate CREB1 DNA-binding activity but enhances the interaction of CREB1 with TAF4/TAFII-130. MECT1 translocates with MAML2 (MasterMind-Like Protein 2) to yield a fusion oncogene: t (11;19) (q21;p13). This translocation occurs in mucoepidermoid carcinomas, benign Warthin tumors and clear cell hidradenomas. The novel fusion product that results disrupts the Notch signaling pathway. The fusion protein consists of the N-terminus of MECT1 joined to the C-terminus of MAML2. The reciprocal fusion protein consisting of the N-terminus of MAML2 joined to the C-terminus of MECT1 has been detected in a small number of mucoepidermoid carcinomas. Multiple isoforms have been reported for the MECT1 protein. Tissue specificity: Highly expressed in adult and fetal brain. Located to specific regions such as the prefrontal cortex and cerebellum. Very low expression in other tissues such as heart, spleen, lung, skeletal muscle, salivary gland, ovary and kidney.

Ver Producto